Engimmune Therapeutics appoints Dr. Lars Nieba as Chief Executive Officer

Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today announces the appointment of Dr. Lars Nieba as Chief Executive Officer. Dr. Søren Mouritsen, co-founder and previous CEO, steps down in a planned transition. Dr. Lars Nieba brings more than 25 years of experience in […]

Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health

Ferring Pharmaceuticals and BioInnovation Institute announce a new strategic collaboration to accelerate innovation in women’s health. BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source and potentially fund and incubate early-stage […]

NeoPhore signs research collaboration with The Institute of Cancer Research, London

London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic collaboration agreement with Professor Chris Lord’s lab at The Institute of Cancer Research, London. The collaboration will use NeoPhore’s proprietary small molecule inhibitors of DNA mismatch repair (‘MMR’) to investigate single agent activity against tumours […]

Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline

New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million Funds will be used to advance clinical pipeline and further build Ariceum Therapeutics Olivier Litzka from Andera Partners and Christoph Massner from Earlybird Venture Capital to join the Ariceum non-executive Board of Directors  Berlin, Germany, 18 April […]

Futura Medical Announces MED3000, Eroxon® UK Launch

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health, today announces that its breakthrough, topical gel formulation for the treatment of erectile dysfunction (ED), MED3000, under the brand name Eroxon®, is now […]

© Optimum Strategic Communications.